UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE BECOMES A GENEGO CENTER OF EXCELLENCE

St. Joseph, Michigan, July 15th, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, today announced that the University of Miami Miller School of Medicine has become a certified GeneGo Center of Excellence (COE). Miller School of Medicine researchers will have access to GeneGo’s MetaCore, training and advanced support. COE will provide a pathway analysis environment and support for all the school’s researchers. They will also act as a training facility for GeneGo in the University of Miami.

“We are looking forward to working with GeneGo as the company provides the kind of forward-looking bioinformatics software that we are excited to use,” said Sawsan Khuri, Ph.D., assistant research professor at the Center for Computational Science at the University of Miami Miller School of Medicine. “The technology will be extremely useful for researchers here, especially those at the Miami Project to Cure Paralysis and the Miami Institute for Human Genomics, both of which will benefit greatly from the collaboration with GeneGo as we work toward new scientific breakthroughs.”

“The University of Miami has some important thought leaders in this field and we are pleased to be working with them” said Julie Bryant, Vice President of Business Development at GeneGo. “The school of medicine works with one million patients annually and it is encouraging that we can help them to improve their quality of life.”

Download this press release in PDF format.

YALE KECK MICROARRAY CENTER BECOMES A GENEGO CENTER OF EXCELLENCE

St. Joseph, MI. July 8th, 2008 – GeneGo, Inc., the leading systems biology tools company, announced today that Keck Microarray Center at Yale has become a certified GeneGo Center of Excellence (COE). Yale researchers will have access to GeneGo’s MetaCore, training and advanced support.

The W. M. Keck Foundation Biotechnology Resource Laboratory (Keck Lab), one of the largest biotechnology laboratories of its kind in academia, is a world leader in the field of genomics and proteomics. The Keck Microarray Resource is also a part of the NIH-Neuroscience supported Yale Microarray Center for Research on the Nervous system. The Yale Microarray Center is one of four national centers which together form a Consortium that provide gene expression and genotyping services at significantly reduced costs to approximately 10,000 NIH-funded neuroscientists from 15 branches of NIH that are part of the NIH-Neuroscience Blueprint.

It is anticipated that MetaCore will be used at Yale to study basic and translational research; cancer biology; neuroscience research; and other clinical conditions. Overall the COE will provide a pathway analysis environment and support for all the University’s researchers and will also act as a training facility for GeneGo.

“MetaCore is being heavily used by our users and we find it to be very intuitive, easy to use and powerful tool for performing pathway analysis of the microarray data,“ said Dr Shrikant Mane, Director of Keck Microarray Resource.

“Neurosciences is one of the key diseases we have chosen to focus on this year and working with Yale is important to GeneGo as they are a leader in this field,” said Julie Bryant, GeneGo’s VP of Business development. “We are very pleased to have them as a GeneGo Center of Excellence.”

Download this press release in PDF format.

VTT TECHNICAL RESEARCH CENTRE OF FINLAND LICENSES METACORE FROM GENEGO FOR CANCER RESEARCH AND DIAGNOSTICS

St. Joseph, MI. June 24th, 2008 – GeneGo, Inc., the leading systems biology tools company, announced today that VTT has licensed MetaCore^TM. VTT develops novel high-throughput methods for cancer research, drug discovery and diagnostics. The focus is in investigating mechanisms of cancer development and progression, identification of therapeutic targets and exploration of the mechanism of action of anti-cancer compounds. VTT will utilize MetaCore and MetaDrug in high-throughput compound screening, RNA interference experiments, cell biology and bioinformatics projects to identify pathways and networks important in translational cancer research.

There are 85 researchers and staff members working in VTT’s Medical Biotechnology Knowledge Centre in Turku. The research is funded by the European Commission and the Academy of Finland. VTT accommodates two EU Marie Curie Centre of Excellence teams and coordinates the Academy of Finland Centre of Excellence for translational genome-wide biology. Further information on VTT: http://www.vtt.fi.

“VTT was our first customer in Finland and an important internationally recognized cancer research center,” said Julie Bryant, GeneGo’s VP of Business development. “We have seen a growing need for analysis platforms focused in disease areas recently. We responded by developing disease pathway ontologies, biomarker and drug databases and new interactome analysis tools. We are pleased that our expertise in cancer is appreciated by professional molecular oncologists at VTT.”

Download this press release in PDF format.

GENEGO IS AWARDED NCI GRANT FOR DEVELOPMENT OF SYSTEMS BIOLOGY PLATFORM FOR INTEGRATIVE DATA ANALYSIS IN CANCER

St Joseph, Michigan, June 17th, 2008 - GeneGo Inc., a leading provider of databases, software and services in systems biology, announced today that they were awarded a Phase I SBIR from National Cancer Institute (NCI) for the development of a platform for functional data analysis in cancer. GeneGo will collaborate with investigators at Dana- Farber Cancer Institute, Boston on the project. The system, MetaMiner (Oncology) will combine pathway and network analysis tools, act as a OMICs data repository and have advanced statistical tools based on functional descriptors.

“MetaMiner (Oncology) is a new generation pathway analysis tool, specifically tailored for biologists, clinicians and chemists working in different cancer areas,” said Yuri Nikolsky, CEO of GeneGo and the grant’s PI. “Neoplasms are tremendously complex diseases, with many hundreds of perturbed pathways, both in terms of gain and loss of functions. We need to understand in a database structure the causal relationships between the involved pathways and the dynamics of pathway activation during tumorigenesis. These are two main goals of the MetaMiner project.”

“There are many “generic” pathway tools on the market, helpful to some extent in cancer data analysis. However, none of them is centered around cancer biology, which is essential,” said Kornelia Polyak, an Associate Professor at Dana-Farber Cancer Institute and a consultant on the grant. “Another focus will be on the development of pathwaybased tools for integration of different types of OMICs data – somatic mutations, high copy number genes, epigenetics, gene expression, proteomics and metabolomics.”

Download this press release in PDF format.

KINEMED LICENSES GENEGO'S METACORE

St. Joseph, Michigan, June 10th, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that KineMed Inc. has licensed MetaCore for application to its ongoing multi-center Phase II prognostic study of chronic lymphocytic leukemia (CLL). KineMed’s kinetic biomarker of CLL flux as a predictor of disease course is intended to stratify indolent (simmering) versus aggressive disease.

“KineMed’s biological pathway insights and GeneGo’s database for systems biology link network complexity to physiologic phenotypes and disease genotypes which is one of the primary goals for personalized medicine. These insights will answer the challenge of determining the right medicine for the right patient at the right time”, said Gregory Hayes, Ph.D., Director of Oncology Research at KineMed. GeneGo’s genetic pathway database aligns with KineMed’s phenotypic pathway analysis and facilitates identification of genetic polymorphisms and expression patterns that directly link genetics with KineMed’s in vivo disease biomarker.

“Building cancer specific pathway analysis software and databases is a key focus area for GeneGo this year, ” said Julie Bryant, VP business development. " We have a lot of expertise in this area that is reflected in our grants and publications in Science and Cancer cell".

Download this press release in PDF format.

GENEGO EXTENDS AGREEMENT WITH MERCK & CO., INC.

St. Joseph, Michigan, June 3rd, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Merck & Co., Inc. has extended its global enterprise agreement. This agreement provides Merck with access to GeneGo’s content through MetaBase which includes access to MetaCore and MetaDrug content and GeneGo’s internal database of disease biomarkers.

“Effective use of powerful systems biology data mining & analysis solutions have become an essential component of modern day drug discovery and development,” said Julie Bryant, VP business development. "Merck is one of our first customers and we are pleased that they have chosen to renew and extend their agreement."

Download this press release in PDF format.

GENEGO’S FIRST CUSTOMER IN HONG KONG; THE CHINESE UNIVERSITY OF HONG KONG

St. Joseph, Michigan, April 22nd, 2008 – GeneGo, Inc., the leading provider of software and databases for systems biology and pathway analysis, today announced that the Chinese University of Hong Kong, Pediatric department will be using GeneGo’s MetaCore™. Broad coverage of biomarkers and drug targets for a large variety of diseases in MetaCore was an important factor for the decision to license MetaCore, as well as species-specific content for the main animal models used in disease research.

“We are very pleased to have the Chinese University of Hong Kong as a customer as we extend our reach in Asia,” said Julie Bryant, VP business development. “Hong Kong is a very sophisticated market with top notch researchers in oncology and other key diseases, and we are glad that the CUHK group has chosen MetaCore. Disease area specific content is one of our important development goals for the next 3 years.”

Download this press release in PDF format.

THE SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE JOINS THE METAMINER CARDIAC CONSORTIUM

St. Joseph, MI. April 15th, 2008 – GeneGo, Inc., the leading systems biology tools company, announced today that The Scripps Translational Science Institute have joined the MetaMiner Cardiac Consortium. The goal of the Consortium is to build the first systems biology and pathway analysis platform for cardiovascular diseases in the world. The Consortium members will vote on deliverables that will include disease specific pathway maps and networks built by experts in the field. GeneGo will also develop relevant ontologies for cardiovascular diseases and drugs. The MetaMiner environment will also serve as a repository for OMICs and other experimental data.

“We are very excited to have The Scripps Translational Science Institute, lead by Dr. Eric Topol, Director as a member. He is a world renowned expert in this field and will provide strong leadership for the project,” said Julie Bryant, GeneGo’s VP of Business development. “The cardiovascular disease area is complex and a challenging field. We believe that MetaMiner Cardiac will have an impact on both basic research and drug discovery in this area.”

Download this press release in PDF format.

GENEGO ROLLS OUT METAMINER CYSTIC FIBROSIS -- THE FIRST DISEASE - SPECIFIC SOFTWARE PLATFORM TO ADVANCE DRUG DISCOVERY

St. Joseph, MI. March 26th, 2008. GeneGo, Inc., the leading systems biology tools company, announced today the release of MetaMiner Cystic Fibrosis, a first of its kind software and database platform designed to help advance drug discovery for cystic fibrosis, a lifethreatening genetic disease. This novel, disease-specific tool will provide the cystic fibrosis research community with state-of-the art methods for integrating and analyzing cystic fibrosis data.

Cystic Fibrosis Foundation Therapeutics, Inc., a non-profit affiliate of the Cystic Fibrosis Foundation, provided funding and guidance to the project with the goal of leveraging systems biology technology and accumulating data in order to accelerate drug discovery for this disease. Cystic fibrosis affects 30,000 people in the United States, and ten million Americans are symptomless carriers of a CF gene.

“MetaMiner Cystic Fibrosis is an important new tool for the cystic fibrosis research community,” said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. “It will allow the integration of important new results with existing literature and speed up the rate of insights that can lead to new therapeutic interventions.”

“We are very pleased to announce the completion of the initial phase of the project,” said Julie Bryant, GeneGo’s VP of Business Development. “We enjoyed working with the Foundation and the team of world-class experts they assembled for this project. In phase one, we built a database of all relevant small experiments information on the disease as well as over 30 cystic fibrosis specific pathway maps and networks. We believe this environment will help find a cure for cystic fibrosis faster as we move in to the next phase of the collaboration”.

MetaMiner Cystic Fibrosis includes off-the-shelf GeneGo products -- MetaCore, MetaDrug and MapEditor -- as well as cystic fibrosis experiments content annotated by GeneGo in the form of disease maps, networks and a database of biomarkers and active compounds. A committee of researchers from the cystic fibrosis community guided the cystic fibrosis-specific annotation under the sponsorship of CFFT. MetaMiner Cystic Fibrosis provides researchers with the ability to interpret emerging data from global experiments, like arrays or proteomics, and link it with published literature on cystic fibrosis.

GeneGo’s MetaMiner Cystic Fibrosis will enable cystic fibrosis researchers to visualize complex information and prioritize research initiatives. It will also help researchers to be open to other interpretations of their experimental data and allow them to rank the significance of their results. Additionally, MetaMiner Cystic Fibrosis will reduce the learning curve for researchers moving into the CF field and permit new investigators to understand outcomes more quickly.

Download this press release in PDF format.

GLAXOSMITHKLINE EXTENDS GENEGO LICENSE AND ADDS NEW PRODUCTS

St. Joseph, MI. February 5th, 2008 – GeneGo, Inc., the leading systems biology tools company, announced today that GlaxoSmithKline has extended their licensing agreement with GeneGo and have added additional capability. This will provide GlaxoSmithKline researchers with global access to MetaCore, MapEditor and MetaBase. MetaCore is GeneGo’s flagship platform for functional analysis of biological OMICs data featuring a comprehensive collection of pathway maps and network models for cellular processes and common diseases. MetaCore is used for target identification, validation, biomarker discovery and knowledge mining. GlaxoSmithKline will also use the platform as a repository of all types of experimental data as well as resulting analyses. All of this information can be easily shared with individuals or groups. MetaBase is direct access to the manually curated database of pathways, networks, ontologies, medicinal chemistry and diseases covering human, mouse and rat. MapEditor is a powerful research tool for creating intereractive custom maps which amalgamate MetaBase knowledge content with proprietary information and data.

“We have a good working relationship with GlaxoSmithKline developing new products such as our pay as you go 1-2-3 Workflow,” said Julie Bryant, GeneGo’s VP of Business development. “We will continue to work closely developing new functionality, tools and content for GlaxoSmithKline.”

Download this press release in PDF format.

U.S. ARMY CENTER FOR ENVIRONMENTAL HEALTH RESEARCH LICENSES METACORE FOR BIOMARKER RESEARCH

St. Joseph, Michigan, January 29th, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the U.S. Army has extended their license of MetaCore. The US Army Center for Environmental Health Research will use MetaCore in its Biomarker Discovery Program to identify novel biomarkers for exposure to TICs/TIMs in order to provide enhanced health surveillance for military personnel.

“We are pleased that institutes on the bleeding edge of technology such as the U.S. Army are using MetaCore in their research” said Julie Bryant, Vice President of Business Development at GeneGo. “Soldiers and other service members can be exposed to a large number of toxic industrial chemicals and materials (TICs/TIMs) from occupational sources, from environmental pollution or as result of military activity. We are proud that our software may help in an ongoing research on environmental pollution dangers”.

Download this press release in PDF format.

FINNISH RED CROSS LICENSES GENEGO PRODUCTS

St. Joseph, MI. January 22nd, 2008 – GeneGo, Inc., the leading systems biology tools company, announced today that the Finnish Red Cross Blood Service has licensed GeneGo’s bioinformatics and chemoinformatics suites MetaCore™ and MetaDrug™, respectively, to be used in a variety of research and clinical projects.

“The entrepreneur knowledgebase behind the merged platform is impressive in the areas of cell adhesion and immunology, which is essential in blood transfusion field,” said docent Jukka Partanen, research director at the FRC Blood Service R&D.

In a joint effort with the Finnish hospitals, FRC Blood Service is collecting clinical information from nearly 70% of the patients receiving blood transfusions in the country, to optimize the blood component usage far beyond 2000 annual diagnoses. Beside the blood group and cell type analysis in disease and pregnancy, we are working with tissue typing of donors and recipients in organ, bone marrow and cord blood and bone marrow stem cell replacement transplantations.

“In the market, we have not found any other manually curated platform where multiple parallel omics data could be submitted in a batch mode in such a systems medicine fashion. We are delighted that the curation does not ignore the non-English journals and reviews patent literature as well. The principle of taking only causality and not mere association into account is critical in the era of NLP text mining servers and HTS data flood,” said Jukka Partanen.

“We are very pleased to be working with such a prestigious organization,” said Julie Bryant VP of Business development for GeneGo. “Disease-centric systems medicine is a natural and logical step in the development of our tools and databases and we are excited to see healthcare organizations such as Finnish Red Cross using it in such practical and important way.”

Download this press release in PDF format.

GENEGO COLLABORATES WITH UNIVERSITY OF ILLINOIS AT URBANACHAMPAIGN TO INCLUDE BOVINE SPECIES INTO METACORE

St. Joseph, Michigan, January 15th, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced they will include bovine orthologs in the next release of MetaCore, in collaboration with University of Illinois Urbana-Champaign whom identified the matching bovine-mouse-rat-human orthologous pairs. The latest version MetaCore 4.5 already includes mouse, rat, fly, worm, yeast, chicken, chimpanzee, Rhesus Macaque, dog, and Malaria plasmodium, making MetaCore the broadest platform available for non-human species research. MetaCore also has a unique rat and mouse specific interaction database called MetaRodent.

“We are happy to collaborate with UIUC on inclusion of bovine orthologs into MetaCore. They did a superb job of ortholog identification”, said Tatiana Nikolskaya, President of GeneGo. “With the rapid advance of sequencing technology, new eukaryotic genomes are becoming available at an increasing rate, and each genome comes with an academic research community. And as each community requests tools for functional analysis of their organism of choice, we see an increasing demand for expansion of the list of species in the database.”

“GeneGo is definitely leading the way for species coverage,” said Julie Bryant, VP of Business Development. “We provide more species and unique interaction databases for mouse and rat that will grow as we continue to innovate.”

Harris Lewin, Principal Investigator and Director of the Institute for Genomic Biology at UIUC had this to say”We were very pleased to work with the team at GeneGo on the identification of cattle orthologs. My group feels that MetaCore is currently the premier product for data mining and pathway analysis. The addition of bovine orthologs of human, mouse and rat genes to MetaCore will make the recently sequenced cattle genome more accessible for functional genomics and systems biology.”

Download this press release in PDF format.

UC BERKELEY EXPANDS MOLECULAR TOXICOLOGY CURRICULUM TO INCLUDE GENEGO'S PLATFORM

St. Joseph, MI. January 8th 20th, 2008 – GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that UC Berkeley will expand the use of its MetaCore/MetaDrug Discovery Platform in their Computational Toxicology course, a required component for Molecular Toxicology majors, and in undergrad honors research programs. The agreement will provide students with chemical structure, network and pathway analysis tools needed to analyze complex omics datasets and to predict and understand the beneficial and potentially harmful effects of chemicals in humans and other species.

“When we designed our Computational Toxicology course a few years ago we anticipated a shift in the future toward ‘systems biology’ that is, looking at the complex interactions of metabolic, genetic, protein, and cellular elements with the goal of modeling entire systems in relation to chemical stresses,” said Dale Johnson, Pharm.D., Ph.D., Adjunct Professor, who designed and teaches the Computational Toxicology course. “The complexity of these chemical/biological interactions resulting from environmental exposures, food sources, or pharmaceutical compounds, highlights our thinking that an overall systems approach will be necessary if relevant advances are to be made in applying computational solutions. GeneGo has presented us with an outstanding platform that continues to grow in functionality each year. We are extremely pleased to be able to utilize MetaCore/MetaDrug as the core part of our coursework.”

“We are pleased with the decision of UC Berkeley's Department of Nutritional Sciences and Toxicology to include our tools in its curriculum, which is one of the very best in the world,” said Julie Bryant, Vice President of Business Development for GeneGo. “The study of fundamental biology is changing quickly with omics technology and systems level analysis, and these changes affect application fields such as toxicology. UC Berkeley will be educating a new breed of toxicology researchers that are needed for the future success of taking drugs to market.”

“Today’s drug and chemical safety assessment process increasingly leverages information from many different sources,” said Dr. Richard Brennan, GeneGo’s Director of Toxicology. “Molecular toxicologists need to be able to put traditional toxicology measurements in the context of chemical information as well as biochemical, gene expression, protein and metabolite data. Industry needs scientists well-versed in complex systems biology data, and in the powerful and flexible analysis tools increasingly used in safety assessment. UC Berkeley is leading the way in providing training in current and emerging technologies, and we are pleased to be able to contribute to this cutting-edge program.”

Download this press release in PDF format.

GENEGO INTEGRATES WITH CYTOSCAPE

St. Joseph, MI. December 18th, 2007 – GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that its platforms for functional data analysis, MetaCore and MetaDrug, are now integrated with Cytoscape. MetaCore users will now be able to use Cytoscape network visualization tools and have access to dozens of its open source and commercial plug-ins. The integrated solution was presented at the Cytsocape annual meeting in Amsterdam, November 6-9.

Originally developed at the Institute for Systems Biology, Cytoscape is a bioinformatics software platform for visualizing molecular interaction networks and integrating these interactions with gene expression profiles and other state data. Additional features are available as plugins. Plugins are available for network and molecular profiling analyses, new layouts, additional file format support and connection with databases. Plugins may be developed using the Cytoscape open Java software architecture by anyone and plugin community development is encouraged.

“This was an obvious progression from our relationship with the Institute of Systems Biology,” said Julie Bryant, Vice President of Business Development for GeneGo. “The Cytoscape project has grown into, probably, the most advanced and well known developer’s community in systems biology, and we are very glad to participate in it. We know that our tools and content will be of interest for Cytoscape users.”

Download this press release in PDF format.

TNO EXTENDS LICENSING AGREEMENT WITH GENEGO AGAIN

St. Joseph, MI. December 4th, 2007 – GeneGo, Inc., the leading systems biology tools company, announced today that TNO, The European Nutrigenomics Organisation (NUGO) Consortium and The Netherlands Nutrigenomics Consortium (NGC) have extended their agreement with Genego. Further, the recently established Netherlands Toxicogenomics Centre (NTC) will soon acquire MetaCore and MetaDrug for applications in toxicogenomics.

This provides over 20 universities in Europe with access to MetaCore. GeneGo has a unique Rodent version of MetaCore with rat and mouse genes, protein complexes and interactions. This is the first species specific database which is not derived from ortholog matching. This level of detail is crucial for nutritionists and toxicologists who deduce human efficacy and toxicity based on animal models data.

‘TNO is routinely applying omics technologies to better understand the activities of nutrients and toxicants. A strong focus is on statistically and biologically driven bioinformatics towards drawing of relevant biological conclusions. We are coordinating the bioinformatics for the consortia mentioned above. MetaCore is a valuable add on to this portfolio and allows us to better understand omics data in the context of mechanisms of action. Within NuGO and NGC, Metacore is used by researchers in the fields of nutritional systems biology. Within NTC, it is used in the context of a variety of toxicological problems. Through interaction with these scientists, TNO is capable of further strengthen its scientific systems biology backbone in these areas.” said Dr Rob Stierum’ Head Toxicogenomics.

“We have established a close relationship with TNO over the years”, said Julie Bryant, GeneGo’s VP of Business development. “The projects we collaborate on include a study on cholesterol diet and drug effects on atherosclerosis and nutrigenomics. TNO is also using GeneGo products as part of their tox service offerings. We look forward to further collaborations and more publications.”

Download this press release in PDF format.

ELAN PHARMACEUTICALS JOINS GENEGO'S METATOX CONSORTIUM

St. Joseph, MI. November 27th, 2007 — GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that Elan Pharmaceuticals has joined the MetaTox Consortium. The Consortium, led by Dr. Richard Brennan, will be focused on developing systems biology tools for safety assessment of small molecule compounds and biological therapeutics. This effort will include expanding the existing tools in the MetaDiscovery™ platform with toxicity ontologies, developing “knowledge-based” predictive models (functional descriptors), manual reconstruction of toxicity pathways in human and relevant preclinical model species, and the development of simplified workflows for analyzing and reporting systems toxicology data. These tools, unique to the marketplace, will enable the members to leverage their diverse molecular toxicology data in an integrated “systems’ perspective that has not been available until now.

“The MetaTox Consortium is a cost effective vehicle for the members to develop software and expand content in systems toxicology,” said Julie Bryant, Vice President of Business Development for GeneGo. “The Consortium will propose the deliverables, to be voted on and prioritized by the members, and GeneGo will then develop and deliver the agreed-upon content and software with members’ input. All the members joining to date have said that they could not perform this amount of work internally for the membership fee, which helped to justify the business model.”

“Despite the increasing deployment of new technologies probing the molecular basis of chemical toxicity, too many investigational drugs still fail in clinical trials due to human toxicity unseen in pre-clinical safety assessment”, said Dr. Richard Brennan, Director of Toxicology at GeneGo, “The Consortium, which includes representatives from industry and from FDA, believes that part of the problem lies in a lack of appropriate data analysis tools to properly integrate the multiple data types generated by data-rich ‘omics technologies, and to convert findings from cell-based and animal models into meaningful human risk-assessments. We will focus on developing novel predictive models, while expanding our knowledge-base of toxicity information, and developing new software for ‘omics data analysis in a systems biology perspective. Alongside GeneGo’s expertise in identifying and mapping differences in human and model-species biology, these tools will facilitate a better assessment of the potential for human toxicity from preclinical tests, increasing the quality of, and confidence in, new compounds going into clinical trials. They will also contribute to understanding the causes of failure for compounds that drop out of trials, or are withdrawn from the market, for safety reasons, allowing these liabilities to be screened out of follow-up molecules.”

Download this press release in PDF format.

UTRECHT UNIVERSITY LICENSES METADRUG™ FROM GENEGO FOR DRUG INNOVATION

St. Joseph, MI. November 20th, 2007 — GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that Utrecht University will be using MetaDrug™ in their prestige master program for drug innovation. MetaDrug™ is designed for predicting biological effects such as indications, toxicity and off-target effects for new compounds structures. Its content includes xenobiotics with known activity, endogenous metabolites and reactions, as well as pathways, networks and diseases which are important for knowledge-based drug discovery. Our integration to Elsevier MDL’s Discovery Gate also helps find more information about the compounds of interest in patent databases and clinical trial databases.

“Our research students of drug innovation should learn to see the big picture as soon as possible, in order to become effective drug researchers. MetaDrug™ is state-of-the-art, but still very accessible to the novice user,” said Dr Ed Moret. “We really like the support and training they have offered to our students.”

“GeneGo is very serious about including MetaDrug™ in academic environments especially for teaching,” said Julie Bryant, Vice President of Business Development for GeneGo. “Academia pushes the limits of MetaDrug™ which allows us to further adapt it for new areas of medicinal chemistry and they publish new applications that we may not even have thought of using it in such a way.”

Download this press release in PDF format.

ELAN PHARMACEUTICALS, INC. LICENSES SOFTWARE AND DATABASES FROM GENEGO

St. Joseph, MI. October 30th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Elan Pharmaceuticals, Inc. licensed its flagship data analysis suite MetaCore™. The platform will be available to all scientists in research. MetaCore™ is designed for functional analysis of biological and chemistry data. Elan will use MetaCore™ in their neurology and autoimmune programs.

“We are very pleased that Elan chose GeneGo and we have had good interactions so far,” said Julie Bryant, GeneGo’s VP of Business development. “MetaCore™ has substantial knowledge content coverage in the areas of CNS and autoimmune diseases, which the Elan scientists can leverage in their innovative research.”

Download this press release in PDF format.

GENEGO LICENSES METACORE™ DATA ANALYSIS SUITE TO AVEO PHARMACEUTICALS

St. Joseph, Michigan, October 23rd, 2007 — GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that they have licensed their MetaCore™ Data Mining Suite to AVEO Pharmaceuticals. The latest version, MetaCore 4.5™, includes novel GeneGo disease enrichment and functional ontology. MetaCore™ has an in depth knowledge base for human diseases and the unique ability to concurrently visualize gene expression, proteomics, genetic and metabolic data. The suite’s data management system is designed for automated upload and handling of hundreds to thousands of genome-wide files, which makes MetaCore™ a robust OMICs repository platform of choice. MetaCore™ is used in both research and clinical groups in drug development.

“We are pleased that AVEO chose the MetaCore™ suite of products to enhance its analytical capabilities,” says Julie Bryant, Vice President of GeneGo. “AVEO’s vision and focus in cancer drug research and development is inspiring and we believe our MetaCore™ suite of data mining tools will be an asset to their efforts.”

Download this press release in PDF format.

ORGANON EXTENDS METACORE™ LICENSE AND ADDS METALINK™

St. Joseph, MI. October 2nd, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Organon, the human health care business unit of Akzo Nobel, have extended their GeneGo software and database licenses. In addition to extending their MetaCore™ license, Organon has also added MetaLink™ so that they can upload their own interaction data and visualize it in the context of MetaCore’s manually curated content.

GeneGo offers easy to use automated workflows that casual users can use and these are now also available through their new product 1-2-3 workflow™ which is a “pay as you go” business model. GeneGo also covers human, mouse, rat, dog, worm, chicken, fly, chimpanzee and yeast which is very important for our customers.

“GeneGo has demonstrated the capability to develop a good pharma oriented bioinformatics tool in the past years” said Peter Groenen, project manager for pharmacogenetics at Organon. “We have now started to use their software for more advanced projects to support our translational medicine efforts”.

“Organon has been a good, loyal GeneGo customer for years and we are pleased they have extended their license,” said Julie Bryant, GeneGo’s VP of Business Development. “We have received good development feedback from Organon over the years and implemented many of their ideas in MetaCore™”.

Download this press release in PDF format.

GENEGO ENTERS MULTI-YEAR AGREEMENT WITH BRISTOL MYERS SQUIBB FOR ACCESS TO GENEGO SOFTWARE SUITE AND DATABASES

St. Joseph, MI. September 25th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Bristol-Myers Squibb (NYSE: BMY) has licensed access to all major GeneGo products. Using the licensed GeneGo technology, research and development sites within Bristol-Myers Squibb will have the ability to start with chemical compound structures and/or genomics data to address questions from both chemistry and biology domains. Bristol-Myers Squibb can also access GeneGo tools to build their own canonical pathway maps using public, GeneGo, and proprietary data and have those maps included in statistical calculations and overlays. In addition, Bristol Myers Squibb researchers can leverage GeneGo products to overlay their own internal interaction data in the context of manually curated pathways for more elucidation.

“Bristol Myers Squibb is very important to GeneGo as they have excellent scientists who we have been collaborating with,” said Julie Bryant, GeneGo’s VP of Business Development. “We plan to continue this collaborative spirit over the next few years.”

Download this press release in PDF format.

GENEGO AND THE CYSTIC FIBROSIS FOUNDATION COLLABORATE TO ADVANCE UNDERSTANDING OF CYSTIC FIBROSIS

St. Joseph, MI. September 11th, 2007 — GeneGo, Inc. and the Cystic Fibrosis Foundation announced today their collaboration to develop a software suite for the integration and analysis of cystic fibrosis data. GeneGo’s proprietary software combines analytical tools, data content and algorithms for understanding the complex interconnected pathways that are affected in common human diseases.

“We hope this collaboration will better help us to understand the disease and potential therapies at the molecular level,” said Robert J. Beall, Ph.D., president and CEO of the Foundation. “Using computational platforms adds to our arsenal of already existing strategies.”

The new platform, called MetaMiner™ (CF), will include off-the-shelf GeneGo products such as MetaCore™, MetaDrug™, MetaLink™ and MapEditor™. Platforms such as MetaDrug™ can help to solve various problems including a drug’s mechanism of action, toxicity and off-target effects, deduced from the structure and any kind of supplementary omics data. The product is intended to be used by medicinal chemists and biologists active in pre-clinical areas of high content and high throughput screening, bioassays, hit-to-lead. MetaMiner™ (CF) will include cystic fibrosisspecific OMICs and small experiments content annotated by GeneGo, disease maps and networks.

“We are very pleased to work with Cystic Fibrosis Foundation and the academic community which is very well organized and successful in research and drug discovery for the disease. We have a clear direction and end goals that we are focused on,” said Julie Bryant, GeneGo’s vice president of business development. “This collaboration is the first in the series of diseasecentered MetaMiner™ projects which integrate our existing data analysis tools, OMICs data warehousing and disease-specific knowledge base. We have a dedicated group of Ph.D. and M.D. scientists to work on this project.”

The project will be guided by a Cystic Fibrosis Foundation committee with a goal to leverage systems biology technology and accumulated data to advance drug discovery for this disease. MetaMiner™ (CF) is expected to be available by February of 2008 to cystic fibrosis academic researchers and drug development collaborators through access licenses.

Cystic fibrosis is a genetic disease that affects about 30,000 adults and children in the United States. It causes life-threatening lung infections and serious digestive complications. More than 10 million Americans are symptomless carriers of the CF gene.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the leading organization devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, Md., the Foundation funds CF research, has 80 chapter and branch offices throughout the country, and supports and accredits a nationwide network of 115 CF care centers, including 94 adult programs, which provide vital treatments and other CF resources to patients and families. For more information, visit www.cff.org.

Download this press release in PDF format.

NHLBI EXTENDS GENEGO LICENSE AGAIN

St. Joseph, MI. September 4th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that National Heart Lung and Blood Institute have extended their license again. Hundreds of researchers will have access to MetaCore™ at the NHLBI for analysis of different types of “omics” data such as gene expression, proteomics, metabolomics and SNPs and MPSS. MetaCore™ is known for its comprehensive functional ontologies including cellular and molecular processes, canonical metabolic and signaling pathways, diseases and disease networks and biomakers.

The NHLBI Genomic Core supports NHLBI investigators conducting research with the ultimate goal of understanding the pathophysiology of human diseases employing high throughput technologies. As a central part of its role, the core provides computational and research tools to investigators and helps them expand their ability to conduct genomic research through new techniques mapping gene expression data to metabolic and signaling pathways. Currently investigators sift through large gene lists trying to decipher which pathways are affected. Genego’s Metacore™ data mining software would provide statistical, visual and machine learning techniques to rationalize the extensive changes in gene expression due to experimental conditions or disease processes and DNA sequence variations. It is hoped that the application of this Metacore™ analysis program would help us decipher the key molecular mechanisms of disease progression, and offer new diagnostic and therapeutic strategies for the future advancement of molecular-based medicine.

“We are pleased to have a strong, long lasting relationship with NIH as they are the best known research organization in biomedicine,” said Julie Bryant, GeneGo’s VP of Business Development. “Over the years, their valuable feedback has helped GeneGo to develop new features and products, and we look forward to expanding relationships with their labs”.

Download this press release in PDF format.

GENEGO ANNOUNCES LICENSING AGREEMENT WITH BIOGEN IDEC

St. Joseph, MI. August 28th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Biogen Idec (NASDAQ: BIIB) licensed its data analysis suite, MetaCore. Biogen Idec researchers can study their proprietary experimental data in the context of seven functional ontologies and unique merged metabolic/signaling networks. Importantly, MetaCore manually curated content now covers 12 organisms, and enables concurrent analysis of virtually any type of OMICs data including SNPs, MPSS files, microarray gene expression, proteomics, metabolomics and custom interactions.

“Biogen Idec is such a great success story and we are pleased to help them in future achievements,” said Julie Bryant, GeneGo’s VP of Business Development. “The field of mammalian systems biology tools is mature by now, and they had multiple choices. We are glad they chose MetaCore.”

Download this press release in PDF format.

GENEGO INC LICENSES METACORE™ TECHNOLOGY TO PHILIPS

St. Joseph, MI. July 31st 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Philips Research, one of the world’s largest industrial research institutes, has licensed its MetaCore™ technology. MetaCore™ is a very flexible pathway analysis platform that can be utilized with or without experimental data. It contains a lot of domain and disease knowledge that is easily accessible to general users which answers day to day questions of what is upstream or downstream of this gene or how are these metabolites linked via pathways, relevant papers to specific diseases or all papers on a compound binding with a specific ligand.

“We are very pleased with Philips’ decision to license MetaCore™” said Julie Bryant, GeneGo’s VP of Business Development. “We have seen a surge of diagnostic companies, such as Almac Diagnostics becoming GeneGo customers over the last couple of years, and Philips is the latest addition. We welcome the expansion of the scope of systems biology applications beyond drug discovery.”

Download this press release in PDF format.

THE INSTITUTE FOR SYSTEMS BIOLOGY LICENSES METACORE™ FROM GENEGO

St. Joseph, MI. July 24th 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that The Institute for Systems Biology (ISB) has licensed its OMICs data analysis suite, MetaCore™ and 1-2-3 Workflow. All ISB researchers will have access to GeneGo pathway analysis and systems biology tools. MetaCore will be integrated with Cytoscape, an open source network visualization software supported by ISB. GeneGo and ISB also plan to collaborate on several research projects.

ISB is an internationally renowned, non-profit research institute headquartered in Seattle and dedicated to the study and application of systems biology. Founded by Leroy Hood, Alan Aderem and Ruedi Aebersold, ISB seeks to unravel the mysteries of human biology and identify strategies for predicting and preventing diseases such as cancer, diabetes and AIDS. ISB’s systems approach integrates biology, computation and technological development, enabling scientists to analyze all elements in a biological system rather than one gene or protein at a time.

“The manually curated content available from GeneGo is exceptional and will allow us to advance our projects,” said Dr Nat Goodman, a Senior Research Scientist at ISB. “We are initiating several research projects together that will hopefully result in publications.”

“We are happy to welcome ISB as a customer and collaborator,” said Julie Bryant, GeneGo’s VP of Business Development. “ISB, led by Dr. Lee Hood, is the premium academic institution in our field, with outstanding research and vision. We are looking forward to working with them in systems biology of human diseases.”

Download this press release in PDF format.

DR. RICHARD BRENNAN JOINS GENEGO AS DIRECTOR OF TOXICOLOGY

St. Joseph, MI. July 17th, 2007 — GeneGo, Inc., the leading provider of databases, software and services in systems biology, today announced the appointment of Dr. Richard Brennan as Director of Toxicology. Dr. Brennan is a Diplomate of the American Board of Toxicology and brings extensive experience in the pharmaceutical and biotechnology industry, with particular expertise in molecular toxicology and toxicogenomics. Dr. Brennan will lead the MetaTox Consortium, a joint industry and government effort focused on development of systems biology tools for prediction of human toxicity of new compounds. Dr. Brennans previous position was Director of Molecular and Investigative Toxicology at Iconix Biosciences, where he was a member of the team that delivered ToxFX, a toxicogenomics data management and analysis solution. Before that, Dr. Brennan was an Associate Director of Pharmacology and Cell Biology at Cornerstone Pharmaceuticals (Stony Brook, NY) and as Senior Scientist at OSI Pharmaceuticals (Farmingdale, NY). Dr. Brennan holds a Ph.D. in Chemistry from the University of Warwick, UK, and conducted post-doctoral research at the University of Manchester and at the Harvard School of Public Health before joining industry.

“We welcome Richard to GeneGo team,” said Tatiana Nikolskaya, GeneGos founder and CSO. “At this point, the field of mammalian systems biology is getting diversified in specific application areas, such as common human diseases, drug safety and medicinal chemistry. Development of next generation products in these areas requires leaders with solid domain expertise, and Richard is both a Board certified expert toxicologist and a developer of systems analysis tools. The MetaTox project, partially supported by our NIEHS Phase II grant, will include toxicity ontologies, signature networks and functional descriptors models for different types of toxicity, as well as manual annotation of toxicity relevant pathways in human, rat, mouse and in vitro models.”

Download this press release in PDF format.

EXPRESSION ANALYSIS ENTERS AGREEMENT WITH GENEGO TO PROVIDE FUNCTIONAL ANALYSIS SERVICES USING 1-2-3 WORKFLOW™

St. Joseph, MI. July 10th 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Expression Analysis, Inc. will be providing functional analysis (pathways and networks) add-on services to their customers. Expression Analysis is the leading microarray services and solutions provider for clinical trials customers. GeneGo’s “1-2-3 Workflow™” automatically uploads and normalizes genomics data, compares multiple expression datasets to identify their common, similar and unique components, conducts enrichment analysis in multiple knowledge ontologies such as diseases, canonical pathways and functional processes and then calculates the most relevant networks and the focal hub proteins. The end product is a comprehensive Word report which will be supplied as an option with microarray assays delivered by Expression Analysis.

“We are very pleased to be working with Expression Analysis as they offer excellent microarray services using standardized protocols for Affymetrix GeneChip® brand technology,” said Julie Bryant, GeneGo’s VP of Business Development.“1-2-3 Workflow™ is an ideal vehicle for value-add functional analysis for OMICs service organizations as it provides a very comprehensive report quickly and in an easy-to-understand Word format at a reasonable cost.”

“Expression Analysis is committed to being a full-service genomics provider,” said Steve McPhail, CEO and President of Expression Analysis, Inc. “Our standard microarray service includes statistical analyses to identify differentially expressed genes. However, some investigators request help translating the gene list into functional relationships. The GeneGo service will provide this assistance using an established software product. We see it as a natural partnership for both companies and a definite value for our clients.”

About Expression Analysis, Inc.:

Expression Analysis, Inc. (http://www.expressionanalysis.com) is the industry's leading provider of microarray-based genomic services for clinical trials. Specializing in gene expression and genotyping assays on Affymetrix GeneChip® microarrays, the company also provides complementary services using Illumina, Luminex and Applied Biosystems' TaqMan® technology.

Download this press release in PDF format.

MONARCH LIFESCIENCES ENTERS AGREEMENT WITH GENEGO TO PROVIDE PATHWAY ANALYSIS SERVICES USING 1-2-3 WORKFLOW™

St. Joseph, MI. June 19th 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Monarch LifeSciences will be offering pathway analysis add on services to their customers. Monarch is a contract research organization with expertise in protein biomarker discovery, development and validation. The 1-2-3 Workflow™ from GeneGo automatically uploads proteomics data, compares the datasets, identifies common, similar and unique components of the datasets, conducts enrichment analysis in multiple ontologies such as diseases, canonical pathways and functional processes; calculates the most relevant networks and the focal hub proteins. The end product is a comprehensive Word report.

“We are very pleased to be working with Monarch as they offer excellent proteomics services, which is a growing OMICs field,” said Julie Bryant, GeneGo’s VP of Business Development. “Our goal in development of 1-2-3 Workflow™ was to adapt our functional data analysis technology for occasional users, which means automation and ease of use without a compromise on quality. We believe that Monarch LifeSciences’ customers will be very happy with the analysis provided.”

“Our goal is to provide our customers with reliable proteomics data that can easily integrate into their research programs,” said Lauri Caviston, Monarch LifeSciences’ VP of Business Development. “GeneGo provides an excellent tool for taking the data we generate to the next level.”

About Monarch LifeSciences:

Monarch LifeSciences provides services in protein biomarker discovery, development and validation for the pharmaceutical and biotech industries. Monarch’s biomarker discovery services include experimental design, proprietary sample preparation methods and quantification algorithms to ensure the generation of quality data. The LifeMarker™ Assay supports both pre-clinical and clinical applications of biomarkers and provides accurate high throughput analysis of proteins without the need for an antibody. For more information, please visit the company’s web site www.monarchlifesciences.com

Download this press release in PDF format.

CHENOMX AND GENEGO OFFER METABOLOMICS DATA INTEGRATION

Manchester, United Kingdom, June 11, 2007 — Chenomx, Inc., a leading provider of software and compound libraries for NMR-based metabolomics, and GeneGo, Inc., a worldwide leader in data analysis solutions for systems biology and pathway analysis, are pleased to announce a partnership to provide metabolomics data integration between their software products.

This partnership combines Chenomx’s powerful and easy-to-use metabolomics software, Chenomx NMR Suite, with GeneGo’s MetaCore and MetaDrug Discovery platform™, providing researchers with the ability to perform sophisticated pathway analysis and visualization.

“Chenomx’s partnership with GeneGo offers several significant advantages to our shared customers,” explains Jack Newton, Director of Product Development for Chenomx. “First, our customers will now be able to combine Chenomx NMR Suite’s powerful metabolite identification and quantification capabilities with GeneGo’s pathway analysis tools, thereby improving their interpretation and understanding of the underlying biology. This integration also allows our customers to integrate genomic and proteomic data sources with their Chenomx metabolomics data.”

“We initiated this partnership based on customer requests for seamless functional analysis of their NMR and mass spec metabolomics data,” said Julie Bryant VP of business development. “Metabolic data is hugely important in diagnostics and drug discovery, as any major disease fundamentally affects core biochemical pathways. Yet, MetaCore/MetaDrug is the only product in the field which enables direct parsing, pathway and network analysis of human metabolic data and its integration with genomics, proteomics and genetic data. Now, our customers will have this functionality accessed directly from Chenomx software”.

About Chenomx, Inc.

Chenomx, Inc. is a privately-held Canadian company that specializes in the development of complex mixture analysis software for broad application in life science technologies. With world-class expertise in NMR spectroscopy, pharmaceutical sciences, and computer software, Chenomx offers a broad range of software products and compound databases to support the metabolomics communities’ research efforts. Chenomx’s flagship product, Chenomx NMR Suite, provides a rich set of tools for identifying and quantifying metabolites in complex NMR Spectra. More information on Chenomx and its solutions is available at www.chenomx.com.

Download this press release in PDF format.

GENEGO LICENSES MEDCHEM DATABASE FROM GVK BIOSCIENCES

Hyderabad - India & St Joseph, MI, USA, June 2, 2007 — GVK Biosciences (GVK BIO) announced that it has licensed its Medicinal Chemistry Database (MCD) to GeneGo, a leading provider of databases, software and services in systems biology. MCD has over 800,000 small molecule inhibitors and has associated 3 million quantitative SAR information manually extracted from over 42,000 medicinal chemistry journal articles. GeneGo will integrate this data into MetaCore™ and MetaDrug™, designed for biology and chemistry aspects of drug discovery process, respectively

G V Sanjay Reddy, Chief Executive Officer, GVK BIO: “We are excited to be working with Genego, the leading pathway analysis and systems biology company in this space. GeneGo has definitely has been an innovator in this field and we are pleased to be associated with them. Their unique chemistry offering fits well with GVK BIO database collections.”.

Julie Bryant, Vice President Business Development, GeneGo commented: “We are very pleased to work with GVK BIO. GeneGo, like our end users, drug companies, have to make “build versus buy” decisions, but it is difficult to find content that fits our high quality criteria and adds value to the databases we have already assembled. This is the first time we have accepted any third party content”.

Informatics at GVK BIO

The Informatics division is responsible for analyzing data to transform chemical / biological patterns into knowledge. Informatics offers Custom Curation, Cheminformatics and Bioinformatics services to global clients. It also licenses and sells databases to Biotech and Pharma companies. GVK BIO’s clients include 15 of the top 20 Pharmaceutical companies.

About GVK BIO

GVK Biosciences is one of Indias premier Contract Research Organizations, providing an integrated platform of research services across the Pharma R&D value chain to a growing number of global Pharma and Biotech companies. The company combines science, innovation and resources to help clients address their Drug Discovery and Development challenges. Currently the company has more than 1,300 employees spread across facilities in Hyderabad, Chennai and Gurgaon.
www.gvkbio.com

Download this press release in PDF format.

GENEGO AWARDED PHASE II TOXICOGENOMICS GRANT BY NIEHS

St. Joseph, MI. May 15th, 2007 — GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that they have received a $750,000 Phase II SBIR grant from National Institute of Environmental Health Sciences (NIEHS) for the development of functional descriptors for gene expression response to drugs and toxins as part of their MetaTox™ product line.

“Toxicogenomics is a mature OMICs field, with a huge amount of drug response data accumulated in industry and the public domain”, said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. “However, one third of compounds are still withdrawn from clinical trials due to human toxicity unseen in pre-clinical toxicogenomics profiling. We see the problem not in the approach itself, but in data interpretation techniques, heavily focused on statistics-derived gene signatures. In this grant, we propose to develop a new concept of functional descriptors and network models for toxicogenomics data analysis, and we are happy that NIEHS share this vision”.

Download this press release in PDF format.

BOEHRINGER INGELHEIM EXPANDS GENEGO LICENSES TO GLOBAL AGREEMENT

St. Joseph, MI. April 10th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Boehringer Ingelheim have expanded their licensing agreement with GeneGo which now covers global locations and multiple departments. The agreement covers a suite of software tools and databases for functional data analysis MetaCore™, which is used for biomarker discovery, target identification and validation. MetaCore™ features a unique set of tools for parsing, visualization and analysis of metabolic data and generation of merged metabolic/signaling networks starting from compounds structures. Such capability is key for toxicity studies and medicinal chemistry.

“We have been working for Boehringer Ingelheim more than a year and we are very pleased with their decision to expand their licenses. This year, we have already seen a substantial increase in the number of MetaCore™ seats within Pharmaceutical accounts, which is partly due to maturing of functional analysis technology” said Julie Bryant, GeneGo’s VP of Business Development. “We also think that the end users, wet lab scientists, see biologically relevant results using MetaCore™ that they are not getting from other tools.”

Download this press release in PDF format.

GENEGO WINS FROST & SULLIVAN AWARD FOR BIOINFORMATICS OURSOURCING AND COMPETITIVE STRATEGY YIELDING SIGNIFICANT COMPETITIVE MARKET GAINS

St. Joseph, MI. March 13th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that they have been awarded a 2006 competitive strategy and bioinformatics outsourcing leadership award from Frost & Sullivan, competing with 150 other companies in Life sciences. Frost & Sullivan cited that GeneGo’s innovative competitive strategy had yielded significant market gains and their analysts expect such innovations will produce lasting, precedent setting trends. This information was gathered by interviews with the experts in the field, end users and the companies themselves. Frost & Sullivan also state that GeneGo is ahead in terms of innovativeness and product quality and has the unique ability to cover the whole spectrum of systems biology that other companies miss.

“The reason why GeneGo Inc.’s competitive approach in the Bioinformatics market has been considered successful is because this makes the company appear attractive in terms of profitability, sustained commercial viability and technical competence”, says Frost & Sullivan Analyst Sumitha Kannan. “The scientific community perceives the company as having a clear vision of its needs and a strategic focus on potential future growth areas.”

“We are honored to receive this award and understand its importance in this competitive field. This award is yet another validation of the high standards that GeneGo sets in the systems biology and pharmacology field” said Julie Bryant, GeneGo’s VP of Business development. “We would also like to acknowledge help and support from our customers and partners whose feedback is really important in our product development.”

To download the white paper please click here.

Download this press release in PDF format.

GENEGO’S METADRUG™ WON THE BEST IN SHOW NEW PRODUCT AWARD AT THE 2007 MOLECULAR MEDICINE MEETING

St. Joseph, MI. March 7th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that its systems pharmacology product MetaDrug 2.0™ won the “Best in Show” product award at the CHI’s Molecular Medicine Marketplace (MMM) conference held in San Francisco last week. MetaDrug™ was chosen a winner among six other systems biology products by conference attendee votes. MetaDrug™ helps to predict indications, off target effects and human toxicity for novel small molecules compounds using systems level chemoinformatics tools and manually annotated knowledge base of compound-target interactions, diseases, toxic categories, drug and endogenous metabolic pathways and signaling interactions. “We are very pleased with winning this award”, said Julie Bryant, GeneGo’s VP of Business development. “MMM is the most important trade show in our field and is attended by the top experts in systems biology, translational medicine and medicinal chemistry, whose opinion matters a great deal for us. This year, we took a considerable risk with MetaDrug™, our second product, as it competed with the latest versions of flagship suites launched by our competitors at MMM. We are glad this risk paid off”. “MetaDrug™ is a unique platform”, said Tatiana Nikolskaya, GeneGo’s CSO and President. “There are probably a hundred commercial and open source products for pathway and network analysis of biological data but virtually nothing for chemistry. Prediction of biological effects for small molecules is a tough problem. Structure-centered chemoinformatics tools do not help explain systems level effects like disease indications; and simple assembly of ligand-receptor interactions databases are not sufficient either. We spent almost three years developing patent-pending MetaDrug™ technology and we are very glad it is appreciated by the market. We are also grateful to NIH which supported MetaDrug™ with SBIR grants”

Download this press release in PDF format.

GENEGO LAUNCHES “PAY AS YOU GO” 1-2-3 WORKFLOW™ AT THE MOLECULAR MEDICINE TRI CONFERENCE

St. Joseph, MI. February 27th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today the release of a new product, 1-2-3 Workflow™, accessible via a “pay-as-you-go” model. This easy to use workflow provides casual users with an automated comprehensive functional analysis of multiple gene lists in just two clicks. All the processing is done in the background and the customers receive a report in a formatted Word file which can be shared with colleagues.

“We are very pleased to release this new “pay-as-you-go” product,” said Julie Bryant, GeneGo’s VP of Business Development. “We developed it based on many requests from our “Google-generation” customers who want the basic analysis done “within 30 minutes with one click”. The trick was to combine the “ease of use” functionality with high quality analysis GeneGo is known for and sophistication of algorithms necessary for analysis of genome-wide datasets accessing the highest quality content in MetaCore™”

“1-2-3 Workflow™ is not about stripping-down functions of our larger product, MetaCore™&rdqou;, says Tatiana Nikolskaya, GeneGo’s President and CSO.“You can consider it as a “condensed wisdom” of our data mining projects run in house in several disease areas and toxicity for several years. We wrapped this knowledge and “know how” up into a workflow with several knowledge ontologies for enrichment analysis, the most advanced network building algorithms we have and our experience in finding the most relevant biomarkers and targets”.

Download this press release in PDF format.

ST. JUDE CHILDREN’S RESEARCH HOSPITAL LICENSES METACORE FROM GENEGO

St. Joseph, Michigan, January 30th, 2007 — GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that St. Jude Children’s Research Hospital has licensed its data mining suite MetaCore. The latest version MetaCore 4.2 includes a novel GeneGo ontology of cellular process networks, which goes a step beyond GO ontology which is also available in MetaCore. It contains additional functional processes and more genes have been networked using GeneGo proprietary network algorithms. MetaCore has an in depth knowledge base for pediatric cancer and the unique ability to concurrently visualize gene expression and proteomics data. MetaCore also covers many species including human, mouse, rat, chicken, dog, worm, yeast and chimpanzee. MetaCore spans research, discovery and clinical trials.

Download this press release in PDF format.

GENEGO AND SPOTFIRE PARTNER TO DELIVER FASTER GENOMICS AND CHEMISTRY ANALYSIS

GeneGo’s MetaCore and Spotfire DecisionSite Fully Integrated to Improve Pharmaceutical Discovery Workflow

St. Joseph, Michigan, January 23rd, 2007 — GeneGo, Inc., a leading provider of software and databases for systems biology and Spotfire, the Information Insight CompanySM, today announced that the companies’ flagship products are fully integrated.

The integrated products allow users to analyze genomics data, including gene expression and proteomics, more quickly and accurately in Spotfire DecisionSite, and launch MetaCore to perform pathway and network analysis. DecisionSite users can also automatically upload chemical compounds into MetaCore and MetaDrug in order to study their biological effects, including mode of action and potential toxicity. The analyzed data can be sent back to DecisionSite, allowing the user to search for additional experiments run in house.

“The integration between DecisionSite and MetaCore and MetaDrug provides our mutual customers with a more powerful environment, improving workflow and accelerating discovery from their experimentation and content,” said Christian Marcazzo, Senior Director of Life Science Analytics for Spotfire. “This integration is a brilliant demonstration of the flexibility of the DecisionSite platform to evolve with the changing needs of our pharmaceutical industry customers.”

“We received numerous requests from our mutual customers for seamless integration with Spotfire. This integration is unique as both GeneGo’s and Spotfire’s products enable concurrent analysis and display of both biological and chemistry data” said Julie Bryant, Vice President of Business Development at GeneGo. “GeneGo has an open partnering philosophy and we always look forward for expansion of our product integration space. We are very pleased with the current project with Spotfire, the dominant player in the data analysis market.”

About Spotfire

Spotfire, the Information Insight CompanySM, is a leading provider of enterprise analytics software that helps professionals quickly discover new and actionable insights in information. For thousands of business professionals faced with day-to-day decisions, Spotfire offers a visual and interactive analytics experience that helps them make decisions with speed and confidence. Distinguished by its ease of use and analytic power, Spotfire software rapidly reveals unseen threats and illuminates new opportunities, creating significant economic value. Spotfire’s customers include industry leaders among the Global 2000 that have deployed Spotfire analytics to gain an information advantage over their competitors. For more information, visit www.spotfire.com.

Spotfire, DecisionSite and Spotfire DXP are trademarks or registered trademarks of Spotfire, Inc., except in the European Community where Spotfire and the products listed are trademarks of Spotfire AB. Other company or product names may be the trademarks of their respective owners.

Download this press release in PDF format.

ALMAC DIAGNOSTICS MULTI YEAR LICENSE AGREEMENT WITH GENEGO

CRAIGAVON, Northern Ireland and St. Joseph, Michigan, December 19th, 2006 – Almac Diagnostics, a division of Almac Group, and GeneGo, Inc., a leading provider of software, databases and services for systems biology, announced today that Almac Diagnostics has licensed their flagship data mining suite, MetaCore™.

The multiple-year agreement will allow Almac Diagnostics’ scientists in the UK and US to use MetaCore™ in the development of novel microarray-based products for the diagnosis and treatment of cancer. Almac Diagnostics’ Genomic Services division that delivers comprehensive genomic services to academic, biotech and pharmaceutical customers will also use MetaCore™.

Almac values the completeness and quality of content coverage in MetaCore™ from signaling ligands to core metabolic pathways, its intuitive interface and comprehensive automated analysis workflows.

“We compared several platforms before we finally decided on GeneGo. MetaCore™ has broad and deep, high quality content coverage, which was important to us. Furthermore its ability to work with mixed IDs is critical for our internal R&D work and service offerings based on our unique DSA™ (patent pending) research tools,” said Dr. Vitali Proutski, Bioinformatics Manager at Almac Diagnostics. “We were also very impressed by GeneGo’s responsiveness and strong customer support which we feel is vital in relationships with our partners.”

“We are very pleased to welcome Almac Diagnostics as a new GeneGo customer. Our experience with them during the thorough evaluation was very positive, with constant communication between Almac Diagnostics and GeneGo scientists,” said Julie Bryant, Vice President of Business Development at GeneGo. “Our products are gaining momentum in clinical diagnostics, both on the development side and among practitioners. Almac combines both as a highly reputable, scientific oriented new generation CRO.”

About Almac Diagnostics

Almac Diagnostics develops, markets and supplies, leading edge genomic products and services. It is a member of the Almac Group, an organization providing services from R&D through clinical development to manufacture of pharmaceutical product. Almac Diagnostics has two divisions:
The Genomic Services division provides all inclusive gene expression, SNP and bioinformatics services to academia, biotech and pharmaceutical companies. These services include analysis on our unique DSA™ research tools, which provide the ability to detect the maximum information in a given cancer type. Almac Diagnostics is the first Authorized Affymetrix Service Provider to successfully gain accreditation to ISO17025 for our comprehensive Gene Expression Microarray and Bioinformatics services.
The Research & Development Division develops, using proprietary DSA™ research tools, new tests that will change the way cancers are managed in the future. These proprietary arrays provide unique information for individual cancer types and represent a stable, long-term platform for the development of clinical diagnostics.
www.almacgroup.com

Download this press release in PDF format.

CHANG GUNG UNIVERSITY UPGRADES AND EXTENDS THEIR AGREEMENT WITH GENEGO TO ACCESS METACORE™ AND MAPEDITOR™

St. Joseph, Michigan, December 12th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, today announced that Chang Gung University (CGU), Taiwan has upgraded their MetaCore™ web portal license to a permanent in house server installation. CGU has also licensed MapEditor™, a new customization product for drawing and editing pathways maps using MetaCore's high quality, manually curated back end content database. An extensive group of CGU researchers will be using MetaCore™ and MapEditor™ for analysis of gene expression, proteomic and metabolomic data in a broad range of life science fields. They also plan to produce their own pathway maps using MapEditor™ that will be accessible to the Chang Gung University research community. The agreement was made possible through GeneGo's Taiwanese distributor Tri-I Biotech.

"GeneGo's MetaCore™ and MapEditor™ is one of the integrated bioinformatics platforms installed in the Chang Gung Bioinformatics Center for analysis of data generated from research projects of different disciplines. Current and ongoing projects include the identification of biomarkers that can reveal the presence of nasopharyngeal carcinoma (NPC) in a blood test; the Trichomonas vaginalis Systems Biology Project and the Acanthamoeba Expressed Sequence Tag Project. These powerful tools will highly improve our research stretch" said Professor Tang.

"We are pleased that Dr. Tang has extended his MetaCore™ license and added our latest product, MapEditor™" said JulieBryant, Vice President of Business Development at GeneGo. "Taiwan is an important, fast growing market for us, as its research is well known in different areas of life sciences."

Download this press release in PDF format.

GENEGO LAUNCHES TWO NOVEL PATHWAY EDITING PRODUCTS, MAPEDITOR™ AND METALINK™

St. Joseph, Michigan, October 24th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced the launch of two new products, MapEditor™ and MetaLink™. The products are add-on modules in the MetaCore™ environment designed for integration, editing and mapping custom interactions data.

MapEditor™ enables the generation of custom pathway maps starting from scratch, converting a network in to a pathway map or editing one of the existing 500 proprietary maps from MetaCore™. This allows GeneGo customers to develop NEW pathway maps based on their proprietary data that is only accessible to their company. GeneGo’s maps are becoming the industry standard and are currently widely available via the iPath™ Online BioAtlas from Invitrogen at www.invitrogen.com/ipath.

MetaLink™ allows users to batch upload their own protein association data produced by yeast-twohybrid screens, gene co-expression, pull-down assays, text mining and other methods in MetaCore™ and build networks on the fly overlaying their interactions in the context of manually curated interactions. The accompanying gene expression and other molecular omics data can be mapped and prioritized on the resulting customized networks.

“MapEditor™ and MetaLink™ were developed in conjunction with our pharmaceutical customers, who needed customization tools to deal with their proprietary experimental interactions data not yet reported in the literature,” said Julie Bryant, Vice President of Business Development at GeneGo. “The new products round up our customization suite of tools which also includes PathwayEditor, launched two years ago. With these additions, the MetaCore™ platform has become a truly universal environment for functional data mining, capable of handling analysis of any type of molecular omics data and gene/protein association data. The main functional blocks in MetaCore™, canonical maps and networks are now completely editable, seamlessly integrated and internally consistent.”

Download this press release in PDF format.

DOW NEUROBIOLOGY LABROATORIES EXTENDS THEIR METACORE™ LICENSES FROM GENEGO

St. Joseph, Michigan, October 17th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Robert S. Dow Neurobiology Laboratories extended their MetaCore™ license. Scientists in RSDNL have been using MetaCore™ for analysis of proteomics and gene expression data for understanding ischemic brain injury and its prevention. MetaCore™ is an expert yet easy to use platform for functional data mining. With intuitive, one-click workflows, it provides bench biologists with a comprehensive overview of pathways, networks, functional modules and processes perturbed in disease and under drug treatment.

“During the past year, we have used MetaCore™ in analyzing our quantitative proteomic data on ischemic rodent brains,” said Dr. An Zhou, a scientist at the RSDNL. “MetaCore™ allows us to efficiently handle multiple sets of high throughput proteomic data with statistics and visual presentation, as well as to identify pathways and networks that are unique to different ischemic conditions of the brain”.

“Research at the Robert S. Dow Neurobiology Labs,” said Dr. Roger Simon, the director of RSDNL, “is concerned with the anatomic, physiologic and neuropathologic aspects of brain and nervous system function, with a focused emphasis on the molecular and cellular mechanisms of neuronal injury and repair that are manifest in stroke and epilepsy. The proteomic and genomic responses to ischemia and particularly the phenomenon of ischemic tolerance and its neuroprotective mechanisms in the brain, are areas of concentrated interest”. Currently there are multiple NIH-funded studies in the RSDNL that address proteomic and genomic changes in the brain after ischemia. The other areas of research interest in the RSDNL include epileptic and traumatic brain injury.”

“We are pleased to see more researchers using proteomics data as well as expression data in design of their experiments” said Julie Bryant, Vice President of Business Development at GeneGo. “Comparing multiple data types is essential; equally important is to depict pathways and networks for biologically meaningful data integration.”

Download this press release in PDF format.

GENEGO INC. IS AWARDED PHASE II NCI GRANT FOR NETWORK BIOMARKERS IN BREAST CANCER

St. Joseph, Michigan, October 3rd, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, announced today that they have been awarded a Phase II SBIR grant from the National Cancer Institute for discovery of new biomarkers implicated in breast cancer based on network analysis. The research program includes a novel large scale gene expression and genotyping study to be run at Mayo Clinic and data analysis in MetaCore™, GeneGo’s flagship data mining platform.

“We are very happy to receive this Phase II award from NCI in the current highly competitive environment as it validates our commitment to scientific research and our novel, innovative ideas in pathway analysis”, said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. “In Phase I, we made some exciting new findings in sub-categorization of breast cancers based on network analysis of previously published microarray expression data. However, the biomarkers found in such “metaanalysis” have to be validated in a new design study in a stringent clinical environment. We are pleased to collaborate with Mayo Clinic, a world leading institution in clinical and research oncology. The microarray and genotyping assays will be conducted at Mayo labs, and the analysis will be performed with state-of-the art translational medicine and systems biology tools”.

Download this press release in PDF format.

MERCK KGAA EXPANDS AND EXTENDS THEIR LICENSE OF METACORE™ FROM GENEGO

St. Joseph, Michigan, September 26th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Merck KGaA, Germany, (in the U.S.: EMD) has expanded their MetaCore™ license to allow all Merck KGaA employees to access MetaCore™ and the license is in perpetuity. Merck KGaA values the completeness of content coverage in MetaCore™ from signaling ligands to core metabolic changes, its intuitive interface and the system’s applicability in many therapeutic areas and biomarkers.

“We see MetaCore™ as a further step into systems biology, a novel discipline which holds much promise for pharmaceutical research,” said Dr Friedrich Rippmann, Director of Bio- and Chemoinformatics.

“We are very pleased to expand our relationship with Merck KGaA. Our experience with them as a customer is very positive, with excellent, constructive, feedback and open exchange of development ideas” said Julie Bryant, Vice President of Business Development at GeneGo. “Now, more groups at Merck KGaA will be able to use MetaCore™ in both early discovery and new compound safety testing.”

Download this press release in PDF format.

WASHINGTON STATE UNIVERSITY EXTENDS METACORE™ LICENSES FROM GENEGO

St. Joseph, Michigan, September 19th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Washington State University Tri-cities has extended their license of MetaCore™. MetaCore™’s new release 4.0 has unique features that give researchers a multi-level analysis of experimental data with respect to functional processes, diseases and consensus pathways in just one click.

“We have been loyal MetaCore™ users for quite some time now and we have been able to make significant progress in our projects supported by the Department of Energy’s Low Dose Radiation Research Program. The software helped us to interpret proteomic data from irradiated cells and to identify pathways responsible for cytokine release following radiation exposure. Understanding these pathways is important for both radiation protection standards and effective use of radiation therapy to treat cancer,” said Dr. John Miller, Associate Professor, Washington State University Tri-Cities, and Emeritus staff member at Pacific Northwest National Labs. “We like the openness of MetaCore™ that allows us to understand our data in terms of biological processes, not just lists of identified proteins.” Dr. Miller focuses on biological and environmental research including radiation induced protein release.

“We are very pleased that an exemplary academic such as Professor Miller finds high value in MetaCore™ as a research tool” said Julie Bryant, Vice President of Business Development at GeneGo. “Academic scientists are a fast growing and invaluable customer base for Gen